Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Benazepril and Hydrochlorothiazide · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Benazepril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg |
| 2 | ACTIVE_COMPARATOR | Lotensin HCT® Tablets 20 mg/25 mg |
| Name | Type | Description |
|---|---|---|
| Benazepril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg | DRUG | 20/25mg, single dose fed |
| Lotensin HCT® Tablets 20 mg/25 mg | DRUG | 20/25mg, single dose fed |
Inclusion Criteria: * 1\. Age: 18 years and older. 2. Sex: Male and/or non-pregnant, non-lactating female. 1. Women of childbearing potential must have negative serum -human chorionic gonadotropin (β-HCG) pregnancy tests performed within 14 days prior to the start of the study and on the evening...
Benazepril and hydrochlorothiazide is a fixed-dose combination product containing benazepril hydrochloride and hydrochlorothiazide. It is developed by Viatris Inc. (ticker VTRS) and is also known as Benazepril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg. The combination pairs an ACE inhibitor with a thiazide diuretic in a single oral tablet.
Benazepril and hydrochlorothiazide contains benazepril, which targets angiotensin-converting enzyme (ACE) as an ACE inhibitor. Hydrochlorothiazide is a thiazide-type diuretic. The benazepril component acts through ACE inhibition, while the hydrochlorothiazide component works through a separate diuretic mechanism. The product is a small molecule combination.
Benazepril and hydrochlorothiazide is developed by Viatris Inc., which trades under the ticker VTRS. Viatris is the sponsor associated with the clinical studies of Benazepril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg.
Benazepril and hydrochlorothiazide is in Phase 1 clinical development. The two registered studies of Benazepril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg are both Phase 1 trials, and both are completed. No active trials are ongoing.
Two completed Phase 1 trials have studied benazepril and hydrochlorothiazide: NCT00649597, a fasting study comparing Benazepril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg with Lotensin HCT Tablets 20 mg/25 mg in 56 healthy volunteers, and NCT00649038, a fed study of the same comparison in 24 healthy volunteers. Both were conducted in the United States.